Optic IconOptic Logo
|
SearchCollectionsBenchmarks
Product

Ensifentrine

Name
Ohtuvayre
INN Name
ensifentrine
FDA Approved
Yes

7 clinical trials

1 organization

2 indications

1 document

Indication
Chronic Obstructive Pulmonary Disease
Indication
COVID-19
Clinical trial
A Randomized, Double-Blind, Placebo-Controlled, Two-period Cross-over Study of the Effect of Ensifentrine on Sputum Markers of Inflammation in Patients With COPD
Status: Recruiting, Estimated PCD: 2024-12-01
Clinical trial
A Single-center, Pilot, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Ensifentrine in the Recovery of Hospitalized Patients With COVID-19
Status: Completed, Estimated PCD: 2021-02-15
Clinical trial
A Phase III, Randomized, Double-Blind, Placebo-Controlled Clinical Study to Evaluate the Efficacy and Safety of Ensifentrine Over 24 Weeks in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease
Status: Recruiting, Estimated PCD: 2024-11-01
Clinical trial
A Phase III Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Ensifentrine Over 24 Weeks (With a 48-week Safety Subset) in Subjects With Moderate to Severe COPD
Status: Completed, Estimated PCD: 2022-09-12
Clinical trial
A Phase 1, Open-Label, Single and Multiple Dose Study to Evaluate the Pharmacokinetics, Safety and Tolerability of Nebulized Ensifentrine in Healthy Chinese Subjects
Status: Completed, Estimated PCD: 2023-04-18
Clinical trial
A Phase III Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Ensifentrine Over 24 Weeks in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease
Status: Completed, Estimated PCD: 2022-05-03
Clinical trial
A Study Assessing the Effect of Ensifentrine on CAT™ Scores Over 12 Weeks in Subjects With Moderate to Severe COPD
Status: Not yet recruiting, Estimated PCD: 2024-10-01
Document
DailyMed Label: Ohtuvayre
Organization
Verona Pharma, Inc.